Treating Patients Referred to Academic Centers for CAR T

Opinion
Video

Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.

  1. From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for CAR T-cell therapy from community practices?
    1. Are the processes similar across academic settings?
  2. How do you coordinate care and maintain communication with the academic center during the CAR-T treatment period?
  3. What is your approach to bridging therapy for patients awaiting CAR-T? How do you decide on the appropriate bridging regimen?
    1. How closely do you coordinate with academic centers around bridging therapy considerations and processes?
Related Videos
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
This series features 2 KOLs.
This series features 2 KOLs.
Related Content